drugset / Trial / NCT02177331

Lacidipine in Medical Practice in Patients With Mild to Moderate Essential Hypertension

NCT02177331

Phase 3 Completed 53 enrolled Boehringer Ingelheim
NaSingle-groupOpen-labelTreatment

Summary

In order to confirm the proposed metabolic effect of lacidipine these follow-up study was to provide long-term data on its impact on liver function, glucose homoeostasis and lipid metabolism. Additionally, its adverse drug reactions and antihypertensive effects were to be studied.

Timeline

Start
1995-06
Primary completion
1998-01
Completion

Drugs

EvaluationDrugModalityDoseRoute
Subject Lacidipine Small molecule

Indications